1Lok A S, McMahon B J. Chronic hepatitis B. Hepatology, 2007, 45, 507- 539. 被引量:1
2Hoofnagle J H, Doo E, Liang T J, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology, 2007, 45; 1056-1075. 被引量:1
3Zeuzem S, Buti M, Gane E J, et al. Baseline parameters predict both early virologic response and longer term outcomes for telbivudine treated patients with chronic hepatitis B (the GLOBE study). Hepatology, 2007, 46 (Suppl 1) : 681A. 被引量:1
6Evans A, Riva A, Cooksley H, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology, 2008, 48:759-769. 被引量:1
10Lai C L, Leung N, Teo E K, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology, 2005, 129. 528-536. 被引量:1
8Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
9European Association for the study of the liver . EASL clinical practice guidelines: management of chronic hepatitis B[J]. J Hepatol, 2009, 50: 227 - 242. 被引量:1
10Facke F, Trautwein C. Hepatitis B goes globe: Telbivudine as a new treat- nent option[J]. Hepatology,2008,47(5): 1 786 - 1 787. 被引量:1